Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 17;20(1):95.
doi: 10.1186/s12943-021-01389-5.

A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer

Affiliations

A novel class of tsRNA signatures as biomarkers for diagnosis and prognosis of pancreatic cancer

Fangfang Jin et al. Mol Cancer. .
No abstract available

Keywords: Biomarker; Pancreatic cancer; tsRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Identification of novel tsRNA biomarkers from serum samples of PC patients. A Proportion of changed miRNAs and tsRNAs in serum from PC patients compared with normal controls. B The scatter plot figuratively expresses the changes in tsRNAs expression. C Hierarchical clustering indicates the differences in tsRNA expression profiling between two groups. D The six serum tsRNAs expression in PC patients in the training set. Serum samples from 24 PC patients and 24 controls were collected and subjected to qRT-PCR absolute quantification. E qRT-PCR shows the concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 in 150 PC patients and 100 control individuals enrolled in the validation set. F ROC curves of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 concentrations in serum samples from PC patients versus healthy controls. G Comparison of the diagnostic values of 2-tsRNA signature with CA19-9 and CEA in pancreatic cancer. H ROC analysis estimates the diagnostic value of 2-tsRNA signature in early stage pancreatic cancer. I qRT-PCR shows the serum concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 in other types of diseases [including 31 PC patients, 48 HCC patients, 60 breast cancer (BRC) patients, 53 non-small cell lung cancer patients (NSCLC), 23 hepatocirrhosis patients, 24 hepatitis patients and 48 control individuals]. **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 2
Fig. 2
Elevated tsRNAsin tumor tissues as independent indicator for predicting survival time of PC patients. A tRF-Pro-AGG-004 and tRF-Leu-CAG-002 expression in PC tissues and paired serum from the same patients (n = 20). B The concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 secreted in the PANC1 culture medium depend on cell number and duration of culture. C PANC1 cells were treatmented with tRF-Pro-AGG-004 or tRF-Leu-CAG-002 inhibitors, the concentrations of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 secreted in the PANC1 culture medium were measured. D Serum tRF-Pro-AGG-004 and tRF-Leu-CAG-002 expression levels in normal mice and PC orthotopic transplantation tumor mice. E Significant correlation between serum tRF-Pro-AGG-004 and tRF-Leu-CAG-002 expression and tumor weight in mice. F tRF-Pro-AGG-004 in patient serum, mouse serum and cell medium is mainly in exosome-free fraction, whereas tRF-Leu-CAG-002 is mainly in exosome. The 60 PC patients in cohort 1 were divided into two groups: shorter-survival group (n = 30) and longer survival group (n = 30). The 75 PC patients in cohort 2 were divided into two groups: shorter-survival group (n = 38) and longer survival group (n = 37). G Representative results for in situ hybridization (ISH) staining of tRF-Pro-AGG-004 or tRF-Leu-CAG-002 in pancreatic cancer (PC) tissues from two groups. H, J ISH scores of tRF-Pro-AGG-004 and tRF-Leu-CAG-002 in two groups from two cohorts (according to positive rate of ISH staining, each sample was scored as 1(0–25%), 2(26–50%), 3(51–75%), 4(76–100%)). I, K Kaplan–Meier overall survival curve of PC patients in two cohorts based on ISH scores of tRF-Pro-AGG-004 and tRF-Leu-CAG-002, and combined tRF-Pro-AGG-004 and tRF-Leu-CAG-002. The optimal cut-offs of ISH was set (ISH score ≥ 3 as high and ISH score < 3 as low). *P < 0.05; **P < 0.01; ****P < 0.0001
Fig. 3
Fig. 3
The production mechanisms and biological functions of the two tsRNAs. A Representative images (left) and statistics analysis (right) of ANG staining from 60 PC tissues (PC) and 60 matched normal adjacent tissue (N). B TCGA dataset analysis of ANG in 179 pancreatic cancerous tissues (PC) and 171 normal pancreatic tissues (Normal). C For survival analyses, IHC intensities of ANG protein in PC tissues and paired normal adjacent tissues (n = 60) were collected and analyzed based on the ratio of IHC intensities (PC tissues/ paired normal adjacent tissues). The median of the data set was calculated as 1.11. And the median value 1.11 was set as cut-off value, > 1.11 as high expression and ≤ 1.11 as low expression. D PANC1 cells were transfected with control siRNA or ANG siRNA. Total RNA was extracted and subjected to qRT-PCR detection of tRF-Pro-AGG-004 and tRF-Leu-CAG-002. E-I Intravenous injection of ANG siRNA inhibited tumor growth and tsRNAs expression in vivo. E Flow chart of the experimental design. The PC orthotopic transplantation model was constructed using PAN02 cells in C57BL/6 J mice. Then the mice were randomly divided into two groups and intravenous delivered cholesterol-modified ANG siRNA (ANG-si) or control siRNA (si-CTL) every 3 days for 4 weeks (7 mice/group). F Tumor image at the day 28. G Quantitative analysis of tumor weights. H, I Quantitative analysis of two tsRNAs levels in tumor and serum in mice from two groups. J-O tRF-Pro-AGG-004 and tRF-Leu-CAG-002 function in pancreatic cancer. J Flow chart of the experimental design. PANC1 cells infected with control lentivirus (Normal), tRF-Pro-AGG-004 and tRF-Leu-CAG-002 overexpression lentivirus (tsRNAs) were implanted subcutaneously into nude mice (5 mice/group), and tumor growth was evaluated on day 30 after implantation. K Tumor images. L, M Quantitative analysis of tumor weights and tumor volumes. N, O Representative images and histogram statistics from EdU and invasion assays of PANC1 cells transfected with tsRNA mimics or inhibitors. *P < 0.05; **P < 0.01; ****P < 0.0001

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs) Genes Dev. 2009;23:2639–2649. doi: 10.1101/gad.1837609. - DOI - PMC - PubMed
    1. Balatti V, Nigita G, Veneziano D, Drusco A, Stein GS, Messier TL, Farina NH, Lian JB, Tomasello L, Liu C-G, et al. tsRNA signatures in cancer. Proc Natl Acad Sci U S A. 2017;114:8071–8076. doi: 10.1073/pnas.1706908114. - DOI - PMC - PubMed
    1. Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu C-G, Croce CM. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer. Proc Natl Acad Sci U S A. 2016;113:5071–5076. doi: 10.1073/pnas.1604266113. - DOI - PMC - PubMed
    1. Honda S, Loher P, Shigematsu M, Palazzo JP, Suzuki R, Imoto I, Rigoutsos I, Kirino Y. Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci U S A. 2015;112:E3816–E3825. doi: 10.1073/pnas.1510077112. - DOI - PMC - PubMed

Publication types

MeSH terms